Cutler Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Cutler Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-540	Closed	-$2.95K	–	5678
2022 Q3	$3K	Sell	540 -14,065	-96%	-$87.7K	﹤0.01%	4114
2022 Q2	$87K	Sell	14,605 -12,414	-46%	-$63.6K	0.01%	1531
2022 Q1	$126K	Buy	+27,019	New	+$80.6K	0.01%	1535
2017 Q2	–	Sell	-784	Closed	-$3K	–	7703
2017 Q1	$3K	Hold	784	–	–	﹤0.01%	5326
2016 Q4	$3K	Hold	784	–	–	﹤0.01%	5503
2016 Q3	$2K	Hold	784	–	–	﹤0.01%	5960
2016 Q2	$2K	Hold	784	–	–	﹤0.01%	5920
2016 Q1	$4K	Sell	784 -210	-21%	-$1.68K	﹤0.01%	5182
2015 Q4	$12K	Buy	+994	New	+$13.3K	﹤0.01%	4005

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Cutler Group's CTIC Position: Q4 2022 in Review

Cutler Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 540 shares — an estimated $2.95K sold.

Cutler Group first reported a position in CTIC in Q4 2015 and held it in 9 quarters. The position peaked at $126K in Q1 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

Cutler Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
Cutler Group sold 540 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $2.95K.
Cutler Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 9 quarters.
Cutler Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $126K in Q1 2022.
145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.